We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

18 hedge funds and large institutions have $16.8M invested in Akari Therapeutics in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

50% more funds holding

Funds holding: 12 → 18 (+6)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

11% more capital invested

Capital invested by funds: $15.1M → $16.8M (+$1.65M)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
18
Holders Change
+6
Holders Change %
+50%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AIC
AWM Investment Company
New York
+$3.3M
2
UOC
UBS O'Connor
Illinois
+$1.43M
3
ECM
Endurant Capital Management
California
+$968K
4
BBA
Baker Bros. Advisors
New York
+$964K
5
Millennium Management
Millennium Management
New York
+$698K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$887K
2
Morgan Stanley
Morgan Stanley
New York
-$42.4K
3
Deutsche Bank
Deutsche Bank
Germany
-$11.6K
4
UBS Group
UBS Group
Switzerland
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$3.02M +$964K +250 +40%
AIC
2
AWM Investment Company
New York
$2.96M +$3.3M +855 New
NMC
3
NEA Management Company
Maryland
$1.96M – – –
VMI
4
VHCP Management II
New York
$1.85M – – –
VC
5
Vivo Capital
California
$1.5M – – –
UOC
6
UBS O'Connor
Illinois
$1.29M +$1.43M +372 New
Millennium Management
7
Millennium Management
New York
$1.13M +$698K +181 +126%
DM
8
Deerfield Management
New York
$1.08M -$887K -230 -42%
ECM
9
Endurant Capital Management
California
$871K +$968K +251 New
HP
10
Hikari Power
Japan
$655K – – –
OAM
11
Oxford Asset Management
United Kingdom
$159K +$174K +45 New
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$130K +$50.1K +13 +52%
Barclays
13
Barclays
United Kingdom
$114K +$127K +33 New
HNB
14
Huntington National Bank
Ohio
$35K – – –
Parallax Volatility Advisers
15
Parallax Volatility Advisers
California
$32K +$34.7K +9 New
Deutsche Bank
16
Deutsche Bank
Germany
$13K -$11.6K -3 -43%
IA
17
IFP Advisors
Florida
$4K +$3.86K +1 New
Morgan Stanley
18
Morgan Stanley
New York
$1K -$42.4K -11 Closed
First Manhattan
19
First Manhattan
New York
$1K +$3.86K +1 New
UBS Group
20
UBS Group
Switzerland
– -$11.6K -3 Closed

AKTX Hedge Fund Activity: Q4 2017 in Review

18 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2017, worth a combined $16.8M — up 11% from $15.1M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new AKTX positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was AWM Investment Company, opening a new position worth an estimated $3.3M. The largest seller was Deerfield Management, cutting an estimated $887K.

  • 18 institutional investors held Akari Therapeutics (AKTX) as of Q4 2017, up from 12 in Q3 2017.
  • Funds reported $16.8M of Akari Therapeutics stock for Q4 2017, up 11% quarter-over-quarter.
  • 8 funds opened new Akari Therapeutics positions in Q4 2017 and 2 closed out, a net change of +6 holders.
  • The largest Akari Therapeutics buyer in Q4 2017 was AWM Investment Company, an estimated $3.3M added.
  • The largest Akari Therapeutics seller in Q4 2017 was Deerfield Management, an estimated $887K sold.

Based on aggregated 13F filings for Q4 2017.